000289192 001__ 289192
000289192 005__ 20240425122528.0
000289192 0247_ $$2doi$$a10.4103/jcrt.jcrt_2178_22
000289192 0247_ $$2pmid$$apmid:38554349
000289192 0247_ $$2ISSN$$a0973-1482
000289192 0247_ $$2ISSN$$a1998-4138
000289192 037__ $$aDKFZ-2024-00626
000289192 041__ $$aEnglish
000289192 082__ $$a610
000289192 1001_ $$0P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aHauswald, Henrik$$b0$$eFirst author$$udkfz
000289192 245__ $$aPrimary and adjuvant intensity-modulated radiotherapy in oropharyngeal carcinoma patients from a single institution.
000289192 260__ $$aMumbai$$bMedknow Publications$$c2024
000289192 3367_ $$2DRIVER$$aarticle
000289192 3367_ $$2DataCite$$aOutput Types/Journal article
000289192 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712064576_21699
000289192 3367_ $$2BibTeX$$aARTICLE
000289192 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289192 3367_ $$00$$2EndNote$$aJournal Article
000289192 500__ $$a#EA:E055#LA:E055#
000289192 520__ $$aTo retrospectively access outcome, adverse events and prognostic factors in oropharyngeal carcinoma (OPC) patients treated with intensity-modulated radiotherapy (IMRT).Ninety-eight OPC patients were treated between 2000 and 2015. Thirty-three patients received definitive and 65 adjuvant radiotherapy. Seventy-one percent had simultaneous chemotherapy. Patients were systematically followed up (mean 114 months, range 19-197 months). Statistical analysis used Kaplan-Meier method, Cox regression analysis, and log-rank test. Adverse events were classified according to common toxicity criteria version (CTCAE) 4.03.The 1-, 5-, and 10-year overall survival rates in the adjuvant vs. definitive cohort were 90.8% vs. 66.7%, 67.4% vs. 33.1%, and 57.7% vs. 16.5%. Survival in the adjuvant cohort was significantly longer than in the definitive cohort (P < 0.00005). Patients <65 years had a significantly longer survival than older patients. Locoregional tumor control rates after 1-, 5-, and 10 years in the adjuvant vs. definitive cohort were 90.2% vs. 66.7%, 82.2% vs 45.4%, and 72.1% vs. 30.3%. Locoregional tumor control in the adjuvant cohort was significantly longer than in the definite cohort (P < 0.005). Distant metastases were diagnosed in 20.4% of all patients. Most patients had mild CTCAE grade 1 and 2 adverse events and mild late adverse events including xerostomia, dysphagia, and lymphedema.Intensity-modulated radiotherapy for OPC is an important part of the treatment algorithm alone and in particular after surgery while the additional benefits of chemotherapy might be age dependent. Despite advanced tumor stages, nearly half of our patients were alive in the long term. The majority of patients had relatively mild chronic adverse events.
000289192 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000289192 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289192 650_2 $$2MeSH$$aHumans
000289192 650_2 $$2MeSH$$aRadiotherapy, Intensity-Modulated: adverse effects
000289192 650_2 $$2MeSH$$aRadiotherapy, Intensity-Modulated: methods
000289192 650_2 $$2MeSH$$aRetrospective Studies
000289192 650_2 $$2MeSH$$aOropharyngeal Neoplasms: radiotherapy
000289192 650_2 $$2MeSH$$aOropharyngeal Neoplasms: drug therapy
000289192 650_2 $$2MeSH$$aOropharyngeal Neoplasms: pathology
000289192 650_2 $$2MeSH$$aRadiotherapy, Adjuvant: adverse effects
000289192 650_2 $$2MeSH$$aCarcinoma: etiology
000289192 7001_ $$0P:(DE-He78)c224fcccfd2d248e4b179ab435aa827a$$aPetrow, Eugen$$b1
000289192 7001_ $$0P:(DE-HGF)0$$aRoeder, Falk$$b2
000289192 7001_ $$aDebus, Juergen$$b3
000289192 7001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b4$$eLast author$$udkfz
000289192 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b5$$eLast author$$udkfz
000289192 773__ $$0PERI:(DE-600)2187633-2$$a10.4103/jcrt.jcrt_2178_22$$gVol. 20, no. 1, p. 375 - 382$$n1$$p375 - 382$$tJournal of cancer research and therapeutics$$v20$$x0973-1482$$y2024
000289192 909CO $$ooai:inrepo02.dkfz.de:289192$$pVDB
000289192 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER RES THER : 2022$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000289192 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000289192 9141_ $$y2024
000289192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c224fcccfd2d248e4b179ab435aa827a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289192 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000289192 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000289192 9200_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000289192 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000289192 980__ $$ajournal
000289192 980__ $$aVDB
000289192 980__ $$aI:(DE-He78)E055-20160331
000289192 980__ $$aUNRESTRICTED